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Purpose: To compare maternal and fetal effects of intravenous phenylephrine and 
ephedrine administration during spinal anesthesia for cesarean delivery in high-risk 
pregnancies.
Source: An extensive literature search was conducted using the US National Library 
of Medicine, MEDLINE search engine, Cochrane review, and Google Scholar using 
search terms “ephedrine and phenylephrine,” “preterm and term and spinal hypoten-
sion,” “preeclampsia and healthy parturients,” or “multiple and singleton gestation and 
vasopressor.” Society of Obstetric Anesthesia and Perinatology meeting abstracts for 
the past 4 years were also searched for relevant studies.
Principle findings: Both phenylephrine and ephedrine can be safely used to coun-
teract hypotension after spinal anesthesia in patients with uteroplacental insufficiency, 
pregnancy-induced hypertension, and in non-elective cesarean deliveries. Vasopressor 
requirements before delivery in high-risk cesarean sections are reduced compared to 
healthy parturients. Among the articles reviewed, there were no statistically significant 
differences in umbilical arterial pH, umbilical venous pH, incidence of fetal acidosis, 
Apgar scores, or maternal hypotension when comparing maternal phenylephrine and 
ephedrine use.
Conclusion: From the limited existing data, phenylephrine and ephedrine are both 
appropriate selections for treating or preventing hypotension induced by neuraxial 
blockade in high-risk pregnancies. There is no clear evidence that either medication is 
more effective at maintaining maternal blood pressure or has a superior safety profile in 
this setting. Further investigations are required to determine the efficacy, ideal dosing 
regimens, and overall safety of phenylephrine and ephedrine administration in high-risk 
obstetric patients, especially in the presence uteroplacental insufficiency.
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inTRODUCTiOn
Maintenance of hemodynamic stability from a sympathetic 
blockade after neuraxial anesthetic techniques for cesarean 
delivery remains a significant clinical problem (1). To counteract 
maternal hypotension, intravenous fluid and vasopressor drugs 
are required.
Historically, ephedrine was considered the preferred vasopres-
sor for management of spinal-induced hypotension in healthy par-
turients. Ephedrine has a relatively slow onset and long duration 
of action compared to phenylephrine and has a predominantly 
β-agonist effect (2). Studies in pregnant ewes demonstrated that 
ephedrine was effective in maintaining arterial blood pressure 
and was associated with greater preservation of uteroplacental 
blood flow compared with other vasopressors (3, 4). Historically, 
phenylephrine, a direct α1-agonist, was avoided due to concerns 
regarding potential uterine blood flow reduction (3). However, 
more recent clinical evidence has consistently demonstrated that 
phenylephrine is effective for maintaining blood pressure during 
elective cesarean deliveries with spinal anesthesia, does not exert 
an adverse effect on the fetus and is associated with a lower rate 
of fetal acidosis compared to ephedrine (5, 6).
In 2002, a quantitative systemic review by Lee et al. examined 
the role of ephedrine and phenylephrine in obstetric patients. 
The authors reported that phenylephrine use was associated 
with higher umbilical arterial (UA) pH values compared to 
ephedrine (2). Subsequent studies conducted in healthy parturi-
ent undergoing elective cesarean deliveries have consistently 
demonstrated that phenylephrine use reduces incidence of fetal 
acidosis compared to ephedrine (5–9) and is more effective at 
maintaining maternal blood pressure (7, 8) and preventing 
intraoperative nausea and vomiting (IONV) (5, 7, 8) compared 
to ephedrine. It has been demonstrated that ephedrine crosses 
the placenta to a greater extent than phenylephrine and stimula-
tion of β-adrenergic receptors in the fetus results in an increased 
fetal metabolic rate (5, 7, 8). Ephedrine-induced fetal tachycardia 
and acidosis appears to depend on dosage and timing of drug 
administration prior to delivery (8–10).
There is a paucity of evidence to guide clinical decisions 
regarding vasopressor use in non-elective cesarean deliveries or 
high-risk parturients. The majority of data that have shaped cur-
rent practices of vasopressor use for spinal-induced hypotension 
have been done in healthy women undergoing elective cesarean 
deliveries. These results cannot necessarily be extrapolated to 
patients diagnosed with impaired uteroplacental blood flow or 
with pregnancy-induced hypertension. This review examines 
the available evidence regarding the efficacy and safety of phe-
nylephrine and ephedrine administration in high-risk cesarean 
deliveries.
MeTHODS
In order to compare maternal and fetal effects of intravenous 
phenylephrine and ephedrine administration during spinal 
anesthesia for cesarean delivery in high-risk pregnancies, an 
extensive literature search was conducted through the United 
States National Library of Medicine using the MEDLINE search 
engine, Cochrane review, and Google Scholar. The search was 
limited to articles published in English prior to October 11, 2016. 
Search terms “ephedrine and phenylephrine,” “preterm and term 
and spinal hypotension,” “preeclampsia and healthy parturients,” 
or “multiple and singleton gestation and vasopressor” were used 
to identify relevant articles. Based on our review, 10 articles that 
investigated vasopressor use in high-risk human pregnancies were 
located, and 5 of these specifically compared the effects of phe-
nylephrine and ephedrine in high-risk obstetric patients. Society 
of Obstetric Anesthesia and Perinatology meeting abstracts for 
the past 4 years were also searched for studies comparing phe-
nylephrine and ephedrine in high-risk parturients.
ReSULTS AnD DiSCUSSiOn
effect on Uteroplacental Blood Flow
In normal pregnancy, a low-resistance vascular pathway to the 
intervillous space develops in order to ensure adequate perfusion 
to meet the needs of the growing fetus and placenta (11–13). 
Increases in uterine and UA vascular resistance detected on 
ultrasound surveillance of high-risk pregnancies are important in 
predicting fetal hypoxia and optimizing fetal outcomes (14–18). 
Placental perfusion and fetal well-being can also potentially be 
impacted by both spinal-induced hypotension and the vasopres-
sors used to prevent this hypotension. Despite evidence in favor 
of phenylephrine in healthy human pregnancies, there is concern 
regarding potential reductions in uteroplacental blood flow with 
administration of α1-adrenergic agonists based on studies in 
healthy pregnant ewes and also pregnant ewes with uteroplacen-
tal insufficiency (3, 19–21). However, there are several limitations 
to the application of animal study results to clinical medicine. 
Different species may have dissimilar adrenergic receptor 
distribution, affinity to vasopressors, or placental transfer of 
vasopressors. The human placenta is characterized by a thinner 
hemomonochorial structure that may allow a greater diffusion 
of ephedrine compared with the synepitheliochorial placenta of 
sheep (22). Additionally, animal experiments were performed 
under isoflurane anesthesia, which might enhance the pulmonary 
vasodilator response to the β-adrenoceptor agonist (23).
Studies on the effects of ephedrine and phenylephrine 
administration on human uteroplacental blood flow have been 
limited to elective cesarean deliveries in uncomplicated pregnan-
cies. Increased resistance in uterine and umbilical artery blood 
flow is associated with higher velocity indices measured by the 
systolic/diastolic (S/D) ratio, the pulsatility index (PI), and the 
resistance index (24). Alahuhta et al. compared the effects of phe-
nylephrine and ephedrine infusions on uteroplacental vascular 
resistance during spinal anesthesia in healthy parturients and 
observed a significant increase in the PI of uterine and placental 
arcuate arteries with phenylephrine administration, though no 
significant change from baseline with ephedrine (18). Recently, 
Guo et  al. examined the effects of phenylephrine or ephedrine 
infusion on placental vascular resistance during spinal anesthesia 
and observed no significant differences in the umbilical artery or 
uterine artery vascular resistance, though the uterine arterial vas-
cular resistance was elevated from baseline in both study groups 
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(25). No significant differences in fetal acid–base status or clinical 
outcomes were noted between phenylephrine and ephedrine 
study groups in either study (18, 25). Ngan Kee et al. investigated 
the effects of ephedrine and metaraminol on uterine vascular 
resistance in healthy parturients undergoing elective cesarean 
section. They found that changes in uterine artery PI were similar 
between groups; however, the patients receiving ephedrine had 
lower UA and umbilical venous (UV) pH values (26).
Based on our review, there have not been any studies spe-
cifically examining the effects of phenylephrine or ephedrine on 
uteroplacental blood flow in patients with preeclampsia, utero-
placental insufficiency, or other high-risk conditions. Moreover, 
an association between prenatal stress and changes in Doppler 
waveform parameters remain inconclusive due to the methodo-
logical limitations of available studies (27). Further investigations 
are necessary to clarify the effect of vasopressors on uteroplacental 
blood flow and fetal well-being in these high-risk settings.
effect on Fetal Outcome
Fetal Outcomes in Uteroplacental Insufficiency
In elective cesarean deliveries, phenylephrine has been associated 
with higher fetal pH compared with ephedrine (5–10), suggesting 
that the effects of phenylephrine on uterine blood flow and the 
fetus are not harmful in healthy pregnant women (28). However, 
there is less evidence available in cases of unscheduled cesarean 
deliveries or in the setting of uteroplacental insufficiency. Based 
on limited available evidence, clinical outcomes of the neonates 
in the presence of potential uteroplacental insufficiency show no 
statistically significant differences in UA and UV pH, incidence 
of fetal acidosis, or Apgar scores between phenylephrine and 
ephedrine administration (Table 1).
A prospective study published by Ngan Kee et al. (29) enrolled 
204 patients who were randomized to receive intermittent boluses 
of either phenylephrine (100 μg) or ephedrine (10 mg) to treat 
episodes of spinal-induced hypotension (defined as systolic BP 
≤100 mmHg) during non-elective cesarean deliveries. Neonatal 
Apgar scores, UA pH, UV pH, and base excess values were not 
significantly different between ephedrine and phenylephrine 
groups, though higher UA and UV lactate concentrations and 
greater incidence of nausea and vomiting were observed in 
patients receiving ephedrine (29). It is important to note that this 
study included patients in which cesarean deliveries were booked 
on the day of surgery, including patients in the labor ward who 
eventually underwent cesarean delivery. Potential fetal compro-
mise was noted in 48 patients in this study. The subanalysis of 
these cases noted similar UA and UV blood gas parameters and 
lactate concentrations in phenylephrine and ephedrine groups, 
with the exception of a lower UA PO2 in the phenylephrine group. 
It is important to note that patients with preexisting hypertension 
or pregnancy-induced hypertension were excluded from this 
investigation (29).
In 2010, Cooper et al. presented a retrospective observational 
study in patients with increased risk of fetal compromise who 
underwent cesarean delivery under spinal anesthesia (30). 
Prophylactic infusions of phenylephrine (33 μg/min) or ephed-
rine and intermittent boluses of either ephedrine (6  mg) or 
phenylephrine (100 μg) were all utilized as the primary means 
of preventing or treating spinal-induced hypotension. Similar 
neonatal Apgar scores and UA pH values were found in patients 
receiving ephedrine, phenylephrine, or no vasopressors (30). 
Notably, the incidence of pregnancy-induced hypertension was 
significantly greater among patients not requiring vasopressors. 
Multiple regression analysis noted the only variable associated 
with altered UA pH was a non-reassuring fetal heart rate (HR) 
tracing prior to cesarean delivery. The authors noted that increased 
incidence of prematurity and shorter spinal-to-delivery intervals 
due to the urgent nature of these cases might affect total dose of 
ephedrine given before delivery. In this study, the ephedrine dose 
was much lower than ephedrine dose used in low-risk cesarean 
deliveries (12 vs. 52  mg), thereby reducing potential adverse 
metabolic effects in the fetus (30). Ngan Kee et al. (29) admin-
istered similar low doses of ephedrine (median 10 mg) in their 
prospective study of non-elective cesarean deliveries compared 
to the total dose of ephedrine (median 54 mg) reported in their 
study of elective cesarean deliveries in low-risk patients (8).
A recent study by Mohta et  al. in patients undergoing 
cesarean deliveries due to potential fetal compromise reported 
data from 106 patients randomized to receive either ephedrine 
(8 mg) or phenylephrine (100 mg) boluses to treat episodes of 
spinal-induced hypotension (systolic BP ≤100  mmHg) (31). 
The number of vasopressor boluses and hypotensive episodes 
were similar between phenylephrine and ephedrine groups. No 
statistically significant intergroup differences were noted in UA 
and UV pH, incidence of fetal acidosis, or Apgar scores. The 
spinal-to-delivery interval in these urgent cesarean deliveries was 
relatively short (mean 9 min), and the authors suggest that this 
may have contributed to the reduced ephedrine requirement and 
decreased fetal drug exposure (31). Patients with preeclampsia 
were excluded from this investigation (31).
Another recent investigation by Jain et  al. prospectively 
compared prophylactic ephedrine infusion (2.5  mg/min) to 
phenylephrine infusion (30 μg/min) to manage spinal-induced 
hypotension in 90 patients undergoing cesarean delivery due 
to signs of acute fetal compromise in the intrapartum period 
(32). The authors reported no differences in fetal acidosis with 
either prophylactic phenylephrine or ephedrine infusion and no 
adverse neonatal outcomes during the period of observation in 
the study (32).
Fetal Outcomes in Hypertensive Disorders  
of Pregnancy
Hypertensive disorders in pregnancy are associated with mater-
nal morbidity and mortality, accounting for 9.4% of pregnancy-
related deaths in the United States during 2006–2010 (33). 
Inadequate trophoblast invasion, leading to incomplete remod-
eling of the uterine spiral arteries, is considered to be a primary 
cause of the placental ischemia (11–13). The resulting elevated 
vascular resistance may account for the differences in reactivity 
of vessels to vasoconstrictor drugs (34). There is concern that 
administering vasopressors may impair uteroplacental blood 
flow in preeclamptic patients given the increased responsiveness 
to vasomotor stimuli.
TABLe 1 | Clinical studies comparing the effect of ephedrine and phenylephrine on “fetal outcome” in the setting of uteroplacental hypoperfusion and hypertensive disorders of pregnancy.
Reference Study inclusion 
criteria
Group N Spinal 
anesthesia 
medication
BP management Outcomes end of 
study
UA, Uv pH neonatal Maternal
Ngan Kee 
et al. (29)
Randomized, 
double-
blinded study
Non-elective 
cesarean section
No vasopressor N = 56 0.5% hyperbaric 
bupivacaine 
10–12 mg with 
FEN 15 µg
Bolus if 
SBP < 100 mmHg
No significant 
differences 
between group PE 
and E
No difference in 1- and 5-min 
Apgar scores or NICU stay
Similar number of 
hypotensive episodes
Uterine 
incision
PE 100 µg bolus N = 74 Higher incidence of 
nausea or vomiting in 
group E
E 10 mg bolus N = 74
Cooper 
et al. (30)
Retrospective 
observational 
study
High-risk 
cesarean delivery
No vasopressor N = 115 0.5% hyperbaric 
bupivacaine 
11–12.5 mg
Not reported No significant 
differences 
between groups
No difference in the incidence of 
5-min Apgar score <7, higher 
incidence of admissions to 
neonatal unit in group PE than E
No difference 
in number of 
hypotensive episodes
Delivery
PE infusion started at 
33 µg/min
N = 97
PE 100 µg bolus N = 51
E infusion N = 12
E 6 mg bolus N = 110
Mohta  
et al. (31)
Prospective, 
randomized, 
double-blind 
study
Emergency 
cesarean section 
due to fetal 
compromise
No vasopressor N = 30 0.5% hyperbaric 
bupivacaine 
10–11 mg
Bolus if 
SBP < 100 mmHg
No significant 
differences 
between group PE 
and E
No significant differences in 
Apgar scores, number of NICU 
admissions, or duration of NICU 
stay
The number of 
hypotensive episodes 
were comparable
Delivery
PE 100 µg bolus N = 53
E 8 mg bolus N = 53
Jain  
et al. (32)
Prospective, 
randomized 
study
Emergency 
cesarean section 
due to acute fetal 
compromise
PE infusion N = 45 0.5% hyperbaric 
bupivacaine 
10 mg with FEN 
25 µg
Bolus if 
SBP < 90% of 
baseline
No significant 
differences 
between group PE 
and E
No difference in number of low 
1-min Apgar scores
Mean SBP was 
comparable
Delivery
30 µg/min + PE bolus 
50 µg
E infusion N = 45 Infusion rate 
reduced if SBP 
110–120%
No warrant further observation in 
pediatric care unit after 24-h F/U
Higher incidence of 
nausea or vomiting in 
group E
2.5 mg/min + E bolus 
4 mg
Stopped if 
SBP > 120%
Ituk  
et al. (37)
Retrospective 
observational 
study
Preeclampsia 
undergoing 
cesarean delivery
PE 100 µg bolus N = 57 0.5% hyperbaric 
bupivacaine 
12 mg with FEN 
25 µg + MO 
250 µg
Not reported No differences in 
neonatal UA pH
No difference Not reported Delivery
E 5 mg bolus N = 89 In 1- and 5-min Apgar score
Higgins 
et al. (38)
Prospective, 
randomized 
study
Preeclampsia 
undergoing 
cesarean delivery
PE infusion  
100 μg/min
N = 54 Not reported Titrated to keep 
SBP > 80% of 
baseline but not 
>160 mmHg
No significant 
differences in 
median UA pH
No difference in 1- or 5-min Apgar 
score or NICU admission
No difference in 
maternal SBP
Delivery
E infusion 8 mg/min N = 54
BP, blood pressure; SBP, systolic blood pressure; PE, phenylephrine; E, ephedrine; UA pH, umbilical artery pH; UV pH, umbilical venous pH; FEN, fentanyl; MO, morphine; F/U, follow-up; NICU, neonatal intensive care unit.
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The incidence of spinal-induced hypotension and the need 
for vasopressor treatment has been noted to be reduced in 
patients with preeclampsia in comparison to both healthy term 
parturients (35) and preterm cesarean deliveries (36). The authors 
of these investigations conclude that preeclampsia-associated 
factors likely account for the lower incidence of hypotension (35, 
36). Average ephedrine doses of 6–10 mg were administered in 
preeclamptic patients without reports of adverse maternal or fetal 
events in these investigations (35, 36). Similarly, a retrospective 
study by Cooper et al. noted that the patients were less likely to 
require vasopressor support for hypotension in the setting of 
pregnancy-induced hypertension (30).
Few studies have directly compared the use of ephedrine and 
phenylephrine for spinal-induced hypotension in preeclamptic 
patients. Cooper et  al. reported that non-reassuring fetal HR 
tracing was the only variable associated with lower UA pH on 
multiple regression analysis, while the use of ephedrine, phe-
nylephrine, or the presence of pregnancy-induced hypertension 
were not associated with alterations in UA pH (30). Ituk et  al. 
also performed a retrospective study comparing phenylephrine 
with ephedrine for managing hypotension after spinal anesthesia 
in preeclamptic patients and reported no difference in UA pH 
between the two study groups (37). However, the ephedrine 
group was characterized by significantly lower gestational age 
at delivery compared to the phenylephrine group (mean 32 vs. 
36  weeks gestation), which may have contributed to reduced 
incidence of hypotension and fewer doses of vasopressors due to 
reduced aortocaval compression by the smaller fetus (37). Similar 
to Cooper et al. (30), this study found that non-reassuring fetal 
heart tracing prior to delivery was the only factor significantly 
associated with lower UA pH (37). An abstract presented at the 
Society of Obstetric Anesthesia and Perinatology (SOAP) 2015 
conference described a prospective study comparing phenyle-
phrine infusion (100 μg/min) or ephedrine infusion (8 mg/min) 
for prevention of spinal-induced hypotension in preeclamptic 
patients. They observed similar UA pH values and incidence of 
fetal acidosis (UA pH < 7.20) in phenylephrine and ephedrine 
study groups and concluded that both vasopressors appear to be 
safe in preeclampsia (38) (Table 1).
Based on the limited data available, it appears that both ephed-
rine and phenylephrine are suitable options for managing spinal-
induced hypotension in patients with hypertensive disorders of 
pregnancy. In women with preeclampsia, there are no apparent 
differences between phenylephrine and ephedrine with regard to 
UA or UV pH, and neonatal outcomes (30, 37, 38). The reduced 
incidence of spinal-induced hypotension in preeclampsia (35, 36) 
and correspondingly lower doses of vasopressors may account for 
these observations.
effect on Maternal Outcome
In the studies reviewed, a variety of phenylephrine and 
ephedrine dosing regimens were used for either prevention of 
spinal-induced hypotension or to treat hypotension in high-risk 
obstetric patients, making it difficult to draw conclusions. Based 
on the limited available evidence, phenylephrine and ephedrine 
appear to be similarly effective in preventing and treating spinal-
induced hypotension in parturients with potential uteroplacental 
insufficiency (29–32) or hypertensive disorders of pregnancy (30, 
37, 38). These findings diverge from studies in healthy parturients, 
in which phenylephrine has been observed to be more effective at 
maintaining maternal blood pressure (7, 8) and preventing IONV 
(5, 7, 8) compared to ephedrine. Compared to healthy pregnan-
cies, there appears to be reduced incidence of hypotension and 
lower vasopressor requirements in patients with uteroplacental 
insufficiency or hypertensive disorders of pregnancy (29–32, 
37), which may be due to a combination of increased incidence 
of prematurity, shorter incision-to-delivery intervals in urgent 
circumstances, or preeclampsia-associated factors.
During spinal anesthesia, preeclampsia patients maintain 
a high vascular tone and typically display a limited decrease 
in mean arterial pressure. Preeclampsia-induced endothelial 
dysfunction leads to increases in endothelin and thromboxane 
production, decreased vasodilator synthesis, and sensitizes the 
vasculature to vasoconstrictors (39). Previous studies indicated 
that spinal anesthesia-induced hypotension was less frequent 
and less severe in preeclamptic patients when compared to nor-
motensive parturients, and minimal doses of vasopressors are 
typically required to restore maternal blood pressure to baseline 
(35, 36, 40) (Table  2). Similarly, Ituk et  al. recently conducted 
a retrospective comparison of phenylephrine and ephedrine for 
management of spinal-induced hypotension in preeclamptic 
patients and observed that approximately 50% of patients did not 
experience hypotension requiring vasopressor treatment follow-
ing spinal anesthesia (37).
Preterm women have less aortocaval compression due to a 
smaller uterine mass, which has been observed to decrease the 
incidence of hypotension and requires smaller doses of vasopres-
sors than those in term pregnancy (41). However, the frequency 
and magnitude of spinal hypotension in preeclampsia patients has 
been observed to be less than in women with preterm pregnancies 
(36). The risk of hypotension among the preeclamptic group was 
almost two times lower than that in the preterm group (relative 
risk = 0.603; 95% confidence interval, 0.362–1.003; P = 0.044), 
and the ephedrine requirement to restore blood pressure to 
baseline level was less than in the preterm group (9.8 ± 4.6 vs. 
15.8 ± 6.2 mg, respectively, P = 0.031) (36).
On the other hand, multiple gestations do not appear to be a 
risk factor for developing hypotension after regional anesthesia 
for cesarean deliveries, despite having a greater uterine mass (42). 
Ngan Kee et al. (43) conducted a prospective study comparing 
vasopressor requirements in twin gestations vs. singletons. There 
were no differences in the incidences of hypotension, nausea, 
vomiting, or vasopressor dosage between study groups (Table 2).
The maternal HR is significantly higher after ephedrine admin-
istration (29, 31, 32), while the incidence of maternal bradycardia 
is significantly greater after phenylephrine administration (29, 
31, 32), though these differences do not appear to significantly 
impact clinical outcomes in high-risk obstetric patients. As a 
selective α1-adrenergic receptor agonist, phenylephrine-induced 
increases in blood pressure activate the baroreceptor reflex and 
cause bradycardia. However, these bradycardic events can be 
minimized or prevented by careful bolus dosing of phenyle-
phrine, or minimizing the infusion rate. Furthermore, with 
these measures in place, no detrimental effects on maternal and 
TABLe 2 | vasopressor use in high risk pregnancy compared to normal pregnancy undergoing Cesarean delivery.
Reference Participants N iv preload neuraxial 
anesthesia 
medication
Upper sensory 
level
non-invasive BP 
monitoring
Definitions of 
hypotension
intervention Outcomes
Hemodynamics iv fluid vasopressor
Aya  
et al. (35)
Severe 
preeclamptics
N = 30 1,500–
2,000 mL 
of lactated 
Ringer’s 
solution over 
20 min
SAB with 0.5% 
hyperbaric 
bupivacaine 
8–12 mg + SUF 
3–5 µg + MO 100 µg
T4 (T3–T5) 2-min intervals from 
SAB for 30 min and 
then at 5-min intervals 
until the end of the 
surgery
SBP < 100 mmHg 
in healthy 
parturients or 30% 
decrease in mean 
BP (in both groups)
E 6 mg bolus 
repeated 
every 2 min
Lower incidence 
of hypotension in 
preeclamptic group
Smaller 
preload 
volume in 
preeclamptic 
group
Less 
ephedrine 
requirement 
in 
preeclamptic 
group
Healthy 
parturients
N = 30 T4 (T2–T5) Incidence of heart rate 
(HR) changes <20% 
was similar
Aya  
et al. (36)
Severe 
preeclamptics
N = 65 1,500–
2,000 mL 
of lactated 
Ringer’s 
solution over 
20 min
SAB with 0.5% 
hyperbaric 
bupivacaine 
8–12 mg + SUF 
3–5 µg + MO 100 µg
T4 (T3–T5) 2-min intervals from 
SAB for 30 min and 
then at 5-min intervals 
until the end of the 
surgery
SBP < 100 mmHg 
in healthy 
parturients or 30% 
decrease in mean 
BP (in both groups)
E 6 mg bolus 
repeated 
every 2 min
Lower incidence 
of hypotension in 
preeclamptic group
No 
significant 
differences 
between 
groups
Less 
ephedrine 
requirement 
in 
preeclamptic 
group
Preterm 
pregnancies
N = 71 T4 (T2–T5) Incidence of HR 
changes <20% was 
similar
Nikooseresht 
et al. (40)
Severe 
preeclamptics
N = 43 10 mL/kg of 
Ringer’s lactate 
solution over 
15–20 min
SAB with 0.5% 
hyperbaric 
bupivacaine 
10 mg + SUF 
2.5–3 µg
T4 (T2–T5) 2-min intervals from 
SAB for 15 min and 
then at 5-min intervals 
until the end of the 
surgery
SBP < 100 mmHg 
in healthy 
parturients or 25% 
decrease in mean 
BP (in both groups)
E 5 mg bolus Lower incidence 
of hypotension in 
preeclamptic group
Smaller 
volumes of 
intravenous 
fluids in 
preeclamptic 
group
Less 
ephedrine 
requirement 
in 
preeclamptic 
group
Healthy 
parturients
N = 37 T4 (T2–T5)
James  
et al. (41)
Term 
pregnancy
N = 25 15 mL/kg of 
crystalloid 
solution
SAB with 0.5% 
hyperbaric 
bupivacaine 
11.25 mg + EPI 2% 
lignocaine with ADR
T3 Not reported SBP < 70% of the 
baseline
Not reported Lower incidence of 
hypotension in preterm 
group
Not reported Not reported
Preterm 
pregnancy
N = 25 T4
Ngan Kee 
et al. (43)
Multiple 
gestation 
pregnancy
N = 40 20 mL/
kg lactated 
Ringer’s 
solution over 
15–20 min
SAB with 0.5% 
hyperbaric 
bupivacaine 
10 mg + FEN 15 µg
T4 (T2–T5) 1-min intervals from 
SAB until uterine 
incision
SBP < 80% of the 
baseline
MET infusion 
0.25 mg/
min + MET 
bolus 0.5 mg
No differences in 
the incidences of 
hypotension
Not reported No 
differences in 
total dose of 
MET
T4 (T3–T4)
Singleton 
pregnancy
N = 60
BP, blood pressure; SBP, systolic blood pressure; MAP, mean arterial pressure; SAB, subarachnoid block; EPI, epidural block; SUF, sufentanil; MO, morphine; FEN, fentanyl; ADR, adrenaline (1:2,000,000); PE, phenylephrine; E, 
ephedrine; MET, metaraminol.
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neonatal outcome have been observed in normal (44) or in high-
risk parturients (29, 31, 32).
COnCLUSiOn
The management of hypotension during cesarean delivery under 
spinal anesthesia remains challenging. The administration of 
vasopressors is often necessary, despite other measures such as 
intravenous crystalloid infusions. Phenylephrine is currently the 
vasopressor of choice for preventing or treating spinal-induced 
hypotension in many practices, as many studies in elective cesar-
ean deliveries have demonstrated phenylephrine to be associated 
with more favorable fetal acid–base status and greater effectiveness 
in preventing hypotension and IONV. However, phenylephrine 
use in the presence of preexisting fetal compromise continues to 
be controversial due to concern of potential uterine blood flow 
reduction.
Based on limited available evidence, it appears that phenyle-
phrine and ephedrine are similarly safe and effective, and both 
may be used to prevent or treat spinal-induced hypotension in the 
setting of potential uteroplacental insufficiency and preeclampsia. 
The current literature does not show any statistically significant 
differences in terms of maternal and neonatal outcomes between 
phenylephrine and ephedrine in these high-risk patients. Further 
randomized double-blind studies are required to further clarify 
the safety and efficacy and determine effective vasopressor dosing 
regimens in high-risk obstetric patients.
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